Display options
Cite
Iasevoli F, Tomasetti C, Buonaguro EF, et al. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol. 2014;12(3):219-38doi: 10.2174/1570159X12666140324183406.
Iasevoli, F., Tomasetti, C., Buonaguro, E. F., & de Bartolomeis, A. (2014). The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Current neuropharmacology, 12(3), 219-38. https://doi.org/10.2174/1570159X12666140324183406
Iasevoli, Felice, et al. "The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment." Current neuropharmacology vol. 12,3 (2014): 219-38. doi: https://doi.org/10.2174/1570159X12666140324183406
Iasevoli F, Tomasetti C, Buonaguro EF, de Bartolomeis A. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol. 2014 May;12(3):219-38. doi: 10.2174/1570159X12666140324183406. PMID: 24851087; PMCID: PMC4023453.
Copy Download .nbib Format: NLM
Share it on

Curr Neuropharmacol. 2014 May;12(3):219-38. doi: 10.2174/1570159X12666140324183406.

The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment.

Current neuropharmacology

Felice Iasevoli, Carmine Tomasetti, Elisabetta F Buonaguro, Andrea de Bartolomeis

Affiliations

  1. Department of Neuroscience, Reproductive and Odontostomatological Sciences - University "Federico II", Naples, Italy.

PMID: 24851087 PMCID: PMC4023453 DOI: 10.2174/1570159X12666140324183406

Abstract

Schizophrenia is one of the most debilitating psychiatric diseases with a lifetime prevalence of approximately 1%. Although the specific molecular underpinnings of schizophrenia are still unknown, evidence has long linked its pathophysiology to postsynaptic abnormalities. The postsynaptic density (PSD) is among the molecular structures suggested to be potentially involved in schizophrenia. More specifically, the PSD is an electron-dense thickening of glutamatergic synapses, including ionotropic and metabotropic glutamate receptors, cytoskeletal and scaffolding proteins, and adhesion and signaling molecules. Being implicated in the postsynaptic signaling of multiple neurotransmitter systems, mostly dopamine and glutamate, the PSD constitutes an ideal candidate for studying dopamine-glutamate disturbances in schizophrenia. Recent evidence suggests that some PSD proteins, such as PSD-95, Shank, and Homer are implicated in severe behavioral disorders, including schizophrenia. These findings, further corroborated by genetic and animal studies of schizophrenia, offer new insights for the development of pharmacological strategies able to overcome the limitations in terms of efficacy and side effects of current schizophrenia treatment. Indeed, PSD proteins are now being considered as potential molecular targets against this devastating illness. The current paper reviews the most recent hypotheses on the molecular mechanisms underlying schizophrenia pathophysiology. First, we review glutamatergic dysfunctions in schizophrenia and we provide an update on postsynaptic molecules involvement in schizophrenia pathophysiology by addressing both human and animal studies. Finally, the possibility that PSD proteins may represent potential targets for new molecular interventions in psychosis will be discussed.

Keywords: Dopamine; NMDA; PSD-95; homer; kalirin; psychosis; shank; synaptic plasticity.

References

  1. Neuroreport. 1995 Apr 19;6(6):869-72 - PubMed
  2. Neuropsychopharmacology. 2000 Sep;23(3):223-39 - PubMed
  3. Handb Exp Pharmacol. 2012;(213):267-95 - PubMed
  4. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):184-97 - PubMed
  5. Brain Res. 2008 Jun 12;1214:23-34 - PubMed
  6. Synapse. 2002 Dec 1;46(3):206-14 - PubMed
  7. Eur J Neurosci. 2005 Jul;22(1):247-56 - PubMed
  8. Trends Pharmacol Sci. 2006 Nov;27(11):574-9 - PubMed
  9. J Neurochem. 2012 Feb;120(3):396-407 - PubMed
  10. Neuroscience. 2007 Jan 5;144(1):239-46 - PubMed
  11. Psychopharmacology (Berl). 2005 Apr;179(1):4-29 - PubMed
  12. Am J Psychiatry. 2008 Dec;165(12):1594-603 - PubMed
  13. Schizophr Res. 2007 Feb;90(1-3):28-40 - PubMed
  14. J Neurophysiol. 2008 Feb;99(2):950-7 - PubMed
  15. J Neurosci. 2009 Mar 4;29(9):2948-60 - PubMed
  16. AMA Arch Gen Psychiatry. 1959 Dec;1:651-6 - PubMed
  17. PLoS One. 2011;6(6):e20631 - PubMed
  18. Schizophr Res. 2005 Oct 1;78(1):87-93 - PubMed
  19. Curr Pharm Biotechnol. 2012 Jun;13(8):1614-21 - PubMed
  20. Neuron. 2007 Nov 21;56(4):640-56 - PubMed
  21. Schizophr Bull. 2012 May;38(3):552-60 - PubMed
  22. Biol Psychiatry. 2007 Oct 1;62(7):747-55 - PubMed
  23. Schizophr Bull. 2012 Sep;38(5):942-9 - PubMed
  24. Neurology. 2011 May 17;76(20):1750-7 - PubMed
  25. Oncogene. 2007 May 3;26(20):2914-24 - PubMed
  26. Genes Brain Behav. 2007 Mar;6(2):141-54 - PubMed
  27. Biol Psychiatry. 2000 Jan 1;47(1):22-8 - PubMed
  28. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9184-9 - PubMed
  29. Front Neurosci. 2007 Oct 15;1(1):97-110 - PubMed
  30. Curr Drug Targets. 2007 May;8(5):583-602 - PubMed
  31. Am J Psychiatry. 2000 Nov;157(11):1811-23 - PubMed
  32. Schizophr Res. 2007 Dec;97(1-3):277-88 - PubMed
  33. Psychopharmacology (Berl). 2010 Oct;212(3):329-44 - PubMed
  34. Neuron. 2001 Jan;29(1):229-42 - PubMed
  35. Nat Neurosci. 2010 Mar;13(3):327-32 - PubMed
  36. J Neurochem. 2006 Aug;98(4):1114-25 - PubMed
  37. Neuropharmacology. 2012 Mar;62(3):1204-20 - PubMed
  38. Nat Med. 2006 Jul;12(7):824-8 - PubMed
  39. Synapse. 2006 Jan;59(1):61-8 - PubMed
  40. Eur J Pharmacol. 1989 Aug 11;167(1):127-35 - PubMed
  41. Mol Psychiatry. 2002;7(2):157-64 - PubMed
  42. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 1;33(5):813-21 - PubMed
  43. J Neurosci. 2005 Apr 6;25(14):3560-70 - PubMed
  44. Hillside J Clin Psychiatry. 1987;9(1):12-35 - PubMed
  45. Neuron. 2003 Jan 23;37(2):263-74 - PubMed
  46. Neuropsychopharmacology. 2010 Sep;35(10):2110-9 - PubMed
  47. Brain Res Mol Brain Res. 2002 Jan 31;98(1-2):124-9 - PubMed
  48. Genes Brain Behav. 2005 Jul;4(5):273-88 - PubMed
  49. Mol Pharmacol. 1994 Dec;46(6):1191-6 - PubMed
  50. Neuropsychopharmacology. 1997 Sep;17(3):141-50 - PubMed
  51. Nat Med. 2004 Mar;10(3):305-9 - PubMed
  52. Synapse. 2009 Oct;63(10):913-20 - PubMed
  53. J Neurosci. 2008 Feb 13;28(7):1697-708 - PubMed
  54. Neurochem Res. 2010 Jul;35(7):994-1002 - PubMed
  55. Lancet. 2009 Jan 3;373(9657):31-41 - PubMed
  56. Arch Gen Psychiatry. 1995 Dec;52(12):998-1007 - PubMed
  57. Psychopharmacol Bull. 2003 Summer;37(3):51-83 - PubMed
  58. Neuropsychopharmacology. 2007 Sep;32(9):1888-902 - PubMed
  59. Am J Psychiatry. 2006 Feb;163(2):185-94 - PubMed
  60. J Neurosci. 2011 Nov 9;31(45):16194-207 - PubMed
  61. Eur J Med Genet. 2009 Sep-Oct;52(5):328-32 - PubMed
  62. Nature. 2011 Apr 28;472(7344):437-42 - PubMed
  63. Mol Pharmacol. 2007 Jun;71(6):1598-609 - PubMed
  64. PLoS One. 2010 Dec 02;5(12):e15107 - PubMed
  65. J Neurochem. 2000 Sep;75(3):889-907 - PubMed
  66. Front Cell Neurosci. 2013 Mar 27;7:31 - PubMed
  67. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13058-63 - PubMed
  68. Am J Psychiatry. 2001 Sep;158(9):1400-10 - PubMed
  69. Eur J Pharmacol. 2010 Aug 10;639(1-3):81-90 - PubMed
  70. Brain Res. 2007 Jan 5;1127(1):108-18 - PubMed
  71. Neurosci Lett. 1981 Jun 12;24(1):93-6 - PubMed
  72. Neurosci Lett. 2007 Apr 6;416(1):1-5 - PubMed
  73. PLoS One. 2012;7(6):e39190 - PubMed
  74. J Neurosci. 2009 Jun 3;29(22):7124-36 - PubMed
  75. Curr Pharm Des. 2012;18(12):1593-604 - PubMed
  76. Psychiatry Res. 2010 May 15;177(1-2):255-60 - PubMed
  77. Neurobiol Dis. 2012 Feb;45(2):796-803 - PubMed
  78. Neuropharmacology. 2013 Nov;74:48-58 - PubMed
  79. J Psychopharmacol. 2008 May;22(3):308-22 - PubMed
  80. Neuroscience. 2006 Jun 30;140(2):699-709 - PubMed
  81. J Neurosci. 1996 Jan;16(1):373-9 - PubMed
  82. Neuroscience. 2001;106(3):579-87 - PubMed
  83. Br J Pharmacol. 2008 Mar;153 Suppl 1:S465-70 - PubMed
  84. Nat Neurosci. 2011 Mar;14(3):285-93 - PubMed
  85. J Psychiatry Neurosci. 2012 Jul;37(4):267-72 - PubMed
  86. Neuropharmacology. 2009 Jan;56(1):90-113 - PubMed
  87. J Neurosci. 2005 Dec 14;25(50):11586-94 - PubMed
  88. Pharmacol Biochem Behav. 1981 Jul;15(1):7-13 - PubMed
  89. Neurosci Lett. 2011 Oct 10;503(3):176-80 - PubMed
  90. Mol Neurobiol. 2012 Oct;46(2):275-96 - PubMed
  91. J Neurosci. 2013 Jan 2;33(1):26-34 - PubMed
  92. Psychopharmacology (Berl). 2013 Jan;225(1):1-19 - PubMed
  93. Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):60-9 - PubMed
  94. Synapse. 2005 Sep 1;57(3):123-31 - PubMed
  95. Brain Res Mol Brain Res. 1998 May;56(1-2):207-17 - PubMed
  96. Eur Neuropsychopharmacol. 2013 Nov;23(11):1516-29 - PubMed
  97. Mol Psychiatry. 2013 Nov;18(11):1185-92 - PubMed
  98. J Neurochem. 2002 Nov;83(4):797-806 - PubMed
  99. Neuropsychobiology. 2009;59(4):239-45 - PubMed
  100. Pharmacol Ther. 2010 Dec;128(3):419-32 - PubMed
  101. J Biol Chem. 2007 May 25;282(21):15778-89 - PubMed
  102. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7863-8 - PubMed
  103. Eur J Pharmacol. 1982 Jan 22;77(2-3):203-4 - PubMed
  104. PLoS One. 2010 Mar 18;5(3):e9755 - PubMed
  105. Front Pharmacol. 2012 Nov 26;3:195 - PubMed
  106. J Neurosci. 2008 Nov 19;28(47):12368-82 - PubMed
  107. Nat Cell Biol. 2004 Mar;6(3):189-96 - PubMed
  108. Mol Pharmacol. 2007 Apr;71(4):1148-58 - PubMed
  109. Trends Neurosci. 2005 Apr;28(4):182-7 - PubMed
  110. J Neurosci. 2009 Dec 9;29(49):15551-63 - PubMed
  111. J Neural Transm (Vienna). 2008 Sep;115(9):1355-65 - PubMed
  112. Annu Rev Biochem. 2007;76:823-47 - PubMed
  113. J Psychiatr Res. 2011 Feb;45(2):234-41 - PubMed
  114. Psychopharmacology (Berl). 1994 Dec;116(4):437-42 - PubMed
  115. J Neurochem. 2010 Jul;114(1):62-73 - PubMed
  116. Nature. 2008 Mar 6;452(7183):93-7 - PubMed
  117. Neuroreport. 2004 Aug 26;15(12):1965-7 - PubMed
  118. Neuropsychopharmacology. 2004 Jul;29(7):1353-62 - PubMed
  119. AMA Arch Neurol Psychiatry. 1959 Mar;81(3):363-9 - PubMed
  120. Trends Mol Med. 2011 Dec;17(12):689-98 - PubMed
  121. Cell. 2009 Apr 3;137(1):159-71 - PubMed
  122. Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):181-94 - PubMed
  123. Curr Pharm Des. 2005;11(27):3561-94 - PubMed
  124. Eur Neuropsychopharmacol. 2010 Mar;20(3):176-86 - PubMed
  125. Genome Biol. 2007;8(2):206 - PubMed
  126. Neuroscience. 2009 Nov 24;164(1):288-99 - PubMed
  127. J Neurosci. 2008 Jan 16;28(3):711-24 - PubMed
  128. Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3317-22 - PubMed
  129. Brain Res. 2007 Feb 2;1131(1):88-96 - PubMed
  130. Nat Med. 2003 Sep;9(9):1180-6 - PubMed
  131. Schizophr Bull. 2012 Sep;38(5):958-66 - PubMed
  132. Am J Psychiatry. 2003 Jun;160(6):1100-9 - PubMed
  133. Arch Gen Psychiatry. 2002 Aug;59(8):705-12 - PubMed
  134. Eur J Pharmacol. 2012 May 5;682(1-3):1-11 - PubMed
  135. Psychopharmacology (Berl). 2013 Mar;226(2):201-15 - PubMed
  136. J Neurosci. 2003 Jul 16;23(15):6327-37 - PubMed
  137. Synapse. 2007 Jun;61(6):429-39 - PubMed
  138. J Psychiatry Neurosci. 2009 Mar;34(2):143-9 - PubMed
  139. J Psychiatr Res. 1999 Nov-Dec;33(6):523-33 - PubMed
  140. Neuropharmacology. 2001 Mar;40(3):460-3 - PubMed
  141. Synapse. 2009 Jan;63(1):42-53 - PubMed
  142. Neuroreport. 2000 Sep 28;11(14):3133-7 - PubMed
  143. Trends Mol Med. 2004 May;10(5):239-44 - PubMed
  144. Adv Exp Med Biol. 2012;970:29-61 - PubMed
  145. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317 - PubMed
  146. Nat Rev Drug Discov. 2006 Aug;5(8):660-70 - PubMed
  147. Neuropharmacology. 2013 Nov;74:23-31 - PubMed
  148. J Neurosci. 1998 Jan 15;18(2):581-9 - PubMed
  149. J Pharmacol Exp Ther. 2009 Nov;331(2):574-90 - PubMed
  150. Neuroscience. 2007 Nov 30;150(1):144-58 - PubMed
  151. Cell. 2002 Oct 18;111(2):219-30 - PubMed
  152. Mol Psychiatry. 2006 Feb;11(2):150-7 - PubMed
  153. Psychopharmacology (Berl). 1995 Jul;120(1):67-74 - PubMed
  154. Neurology. 2008 Mar 18;70(12):964-8 - PubMed
  155. Pharmacol Res. 2008 Apr;57(4):296-302 - PubMed
  156. Behav Pharmacol. 1996 Jan;7(1):3-23 - PubMed
  157. Mol Psychiatry. 2006 Aug;11(8):737-47, 705 - PubMed
  158. PLoS One. 2012;7(12):e52865 - PubMed
  159. Eur Arch Psychiatry Clin Neurosci. 2012 Mar;262(2):117-24 - PubMed
  160. Int Rev Neurobiol. 2004;59:221-54 - PubMed
  161. Neuropsychopharmacology. 2008 Aug;33(9):2175-86 - PubMed
  162. Mol Cell Neurosci. 2006 Aug;32(4):356-65 - PubMed
  163. Neuron. 2001 Jul 19;31(1):115-30 - PubMed
  164. Neurosci Res. 2007 Jun;58(2):145-8 - PubMed
  165. J Neural Transm (Vienna). 2007;114(4):423-6 - PubMed
  166. J Neurosci. 2006 Apr 26;26(17):4690-700 - PubMed
  167. Schizophr Res. 2013 May;146(1-3):177-83 - PubMed
  168. J Biol Chem. 2000 Mar 3;275(9):6395-403 - PubMed
  169. Recent Pat CNS Drug Discov. 2006 Nov;1(3):239-46 - PubMed
  170. Mol Brain. 2008 Sep 10;1:6 - PubMed
  171. Am J Psychiatry. 2009 Jul;166(7):812-20 - PubMed
  172. Am J Med Genet B Neuropsychiatr Genet. 2003 Jul 1;120B(1):18-21 - PubMed
  173. Neuropsychopharmacology. 1998 Aug;19(2):105-13 - PubMed
  174. Arch Gen Psychiatry. 1994 Mar;51(3):199-214 - PubMed
  175. Biol Psychiatry. 2010 Feb 1;67(3):246-54 - PubMed
  176. Eur J Pharmacol. 2001 Jan 26;412(2):127-38 - PubMed
  177. Mol Pharmacol. 2006 Mar;69(3):813-22 - PubMed
  178. Nature. 2011 May 12;473(7346):221-5 - PubMed
  179. Neuropsychopharmacology. 1999 Feb;20(2):106-18 - PubMed
  180. Psychopharmacology (Berl). 2012 Feb;219(4):1065-79 - PubMed
  181. Synapse. 2010 Oct;64(10):794-800 - PubMed
  182. Schizophr Bull. 2012 Sep;38(5):911-3 - PubMed
  183. Curr Pharm Des. 2012;18(12):1580-92 - PubMed
  184. Eur Neuropsychopharmacol. 2012 May;22(5):356-63 - PubMed
  185. J Psychopharmacol. 2011 Jul;25(7):875-87 - PubMed
  186. Int J Neurosci. 2008 Nov;118(11):1609-27 - PubMed
  187. J Neurosci. 2008 Aug 20;28(34):8560-7 - PubMed
  188. Cereb Cortex. 2008 Nov;18(11):2560-73 - PubMed
  189. Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):774-9 - PubMed
  190. J Neurosci. 2004 Feb 4;24(5):1149-58 - PubMed
  191. J Neurosci. 2011 Aug 31;31(35):12554-65 - PubMed
  192. Nature. 2012 Feb 29;483(7388):213-7 - PubMed
  193. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1661-4 - PubMed
  194. Neurochem Res. 2013 Jan;38(1):1-22 - PubMed
  195. Behav Brain Funct. 2012 Jan 06;8:2 - PubMed
  196. J Neurosci. 2000 Jun 1;20(11):4037-49 - PubMed
  197. J Neurosci. 2005 May 4;25(18):4587-92 - PubMed
  198. Neurobiol Learn Mem. 2012 Jan;97(1):17-29 - PubMed

Publication Types